Why the study?
Do patients dying of chronic refractory congestive heart failure receive more life-sustaining treatments compared to those dying of metastatic cancer?
Do patients dying of chronic refractory congestive heart failure receive more life-sustaining treatments compared to those dying of metastatic cancer?
Patients dying of chronic, refractory heart failure receive more life-sustaining treatments and later do-not-resuscitate orders compared to those dying of metastatic cancer, highlighting potential disparities in end-of-life care.
No takes yet. Share an insight, caveat, or question.
Potential disparities in CHF end-of-life care warrant attention; observational data leave open need for prospective trials before practice change.
Tanvetyanon et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: